Assertio Therapeutics (NASDAQ:ASRT) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 175 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $34.21 million which beat the analyst consensus estimate of $31.33 million by 9.20 percent. This is a 34.31 percent increase over sales of $25.47 million the same period last year.
UPDATE: Assertio Therapeutics Q3 Adj. EPS $0.22 Beats $0.07 Estimate
Assertio Therapeutics (NASDAQ:ASRT) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 175 percent increase over earnings of $0.08 per share
Related Posts
Arrowhead Pharmaceuticals Q3 EPS $(0.29) Misses $(0.20) Estimate, Sales $45.89M Beat $37.52M Estimate
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.20) by 45 percent. This is a 123.08 percent decrease over losses of $(0.13) per
Humanigen Says European Commission Selects Co’s Lenzilumab As 1 Of 10 Most Promising Treatments For COVID-19
Humanigen, Inc. (NASDAQ:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, today
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
Praxis Precision Medicines Inc (NASDAQ:PRAX) announced topline results from the Essential1 study evaluating the efficacy, safety, and tolerability of ulixacaltamide (PRAX-944)…